Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Head and Neck Cancer

Free Subscription Articles published in J Clin Endocrinol Metab Retrieve available abstracts of 142 articles: HTML format

Single Articles

December 2025
1. MACHLAH YM, Brandenburg T, Muchalla P, Tiedje V, et al
   Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center.
   J Clin Endocrinol Metab. 2025;111:167-179.
   PubMed     Abstract available
   
   
   November 2025
2. DAN R, Paran N, Vinegrad N, Fraenkel M, et al
   Parity as a Risk Factor for Differentiated Thyroid Carcinoma- A Population-Based Study.
   J Clin Endocrinol Metab. 2025 Nov 24:dgaf642. doi: 10.1210.
   PubMed     Abstract available
   
   
   
3. SONG JX, Xie J, Zhou JX, Zhang YF, et al
   Approach to the Patient With Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1.
   J Clin Endocrinol Metab. 2025;110:3546-3558.
   PubMed     Abstract available
   
   
   
4. YU CY, Chu EH, Lin CH, Chen YC, et al
   Diagnostic Efficiency of Thyroglobulin in Lymph Node Fine-needle Aspiration Washout: A Systematic Review and Meta-analysis.
   J Clin Endocrinol Metab. 2025;110:3569-3587.
   PubMed     Abstract available
   
   
   
5. DEVOUGE AC, Lasolle H, Dupin C, Vergniol J, et al
   Outcomes and Therapeutic Strategies for Head-and-neck Paragangliomas Associated With Succinate Dehydrogenase Mutations.
   J Clin Endocrinol Metab. 2025;110:e4030-e4037.
   PubMed     Abstract available
   
   
   
6. SOTO JACOME C, Arce-Camposano A, Toro-Tobon D, Al Zahidy M, et al
   Drug Repurposing for Reducing the Size of Benign Thyroid Nodules: A Systematic Review.
   J Clin Endocrinol Metab. 2025 Nov 12:dgaf616. doi: 10.1210.
   PubMed     Abstract available
   
   
   October 2025
7. CASALINI R, Romei C, Bottici V, Cappagli V, et al
   Prevalence and genetics of "de novo" MEN2 syndromes.
   J Clin Endocrinol Metab. 2025;110:e3559-e3565.
   PubMed     Abstract available
   
   
   September 2025
8. POZDEYEV N, White SL, Bell CC, Haugen BR, et al
   Artificial intelligence applications in thyroid cancer care.
   J Clin Endocrinol Metab. 2025 Sep 25:dgaf530. doi: 10.1210.
   PubMed     Abstract available
   
   
   
9. XU X, Zhang C, Wang G, Dong B, et al
   Correlation of TgAb With Clinicopathological Features and Unfavorable Efficacy of 131I Ablation in PTC.
   J Clin Endocrinol Metab. 2025;110:e3245-e3251.
   PubMed     Abstract available
   
   
   August 2025
10. CHO YY, Ahn SH, Kim M, Lee EK, et al
    TSH Cut-Offs and Recurrence Risk in Differentiated Thyroid Carcinomas: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2025 Aug 14:dgaf463. doi: 10.1210.
    PubMed     Abstract available
    
    
    
11. BILGIN C, Hibbert R, Oztepe F, Sfeir JG, et al
    Percutaneous Ablation of Parathyroid Adenomas: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2025;110:e3150-e3162.
    PubMed     Abstract available
    
    
    July 2025
12. GREENSPUN BC, Metzger DA, Lee S, Pearson BE, et al
    Long Term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model.
    J Clin Endocrinol Metab. 2025 Jul 15:dgaf391. doi: 10.1210.
    PubMed     Abstract available
    
    
    
13. BODOQUE-CUBAS J, Fernandez-Saez J, Martinez-Hervas S, Perez-Lacasta MJ, et al
    Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-Effectiveness Analysis.
    J Clin Endocrinol Metab. 2025 Jul 12:dgaf399. doi: 10.1210.
    PubMed     Abstract available
    
    
    June 2025
14. HAMIDI S, Maniakas A, Akhave NS, Banuchi VE, et al
    Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues.
    J Clin Endocrinol Metab. 2025 Jun 26:dgaf366. doi: 10.1210.
    PubMed     Abstract available
    
    
    
15. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
    Clinical Significance of Successful Ablation in Follicular Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Jun 4:dgaf326. doi: 10.1210.
    PubMed     Abstract available
    
    
    May 2025
16. NISHIKAWA Y, Oguro F, Suzuki C, Kobashi Y, et al
    Stable iodine intake and thyroid screening outcomes after the Fukushima Nuclear Disaster: an observational study.
    J Clin Endocrinol Metab. 2025 May 29:dgaf312. doi: 10.1210.
    PubMed     Abstract available
    
    
    
17. FRICH PS, Sigstad E, Berstad AE, Opsahl EM, et al
    Ethanol Ablation of Metastatic Lymph Nodes in Patients with Papillary Thyroid Carcinoma - Predictors of Clinical Outcome.
    J Clin Endocrinol Metab. 2025 May 23:dgaf298. doi: 10.1210.
    PubMed     Abstract available
    
    
    April 2025
18. WHITE SL, Jamil T, Bell C, Fishbein L, et al
    Population prevalence of the major thyroid cancer-associated syndromes.
    J Clin Endocrinol Metab. 2025 Apr 15:dgaf236. doi: 10.1210.
    PubMed     Abstract available
    
    
    
19. HIRUMA S, Watanabe N, Noh JY, Hirose R, et al
    Occurrence of Newly Diagnosed Thyroid Cancer Is Not Increased After Radioactive Iodine Therapy for Graves' Disease.
    J Clin Endocrinol Metab. 2025 Apr 11:dgaf231. doi: 10.1210.
    PubMed     Abstract available
    
    
    
20. KU EJ, Lee J, Yoo WS, Bae J, et al
    Long-Term Non-skeletal Complications in Patients with Thyroid Cancer and Hypoparathyroidism Post-total Thyroidectomy.
    J Clin Endocrinol Metab. 2025 Apr 2:dgaf213. doi: 10.1210.
    PubMed     Abstract available
    
    
    
21. DE LEO S, Brigante G, D'Elia S, Censi S, et al
    Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study.
    J Clin Endocrinol Metab. 2025 Apr 1:dgaf190. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2025
22. SHARIQ OA, Waguespack SG, Hamidi S, Kensing BC, et al
    Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Mar 19:dgaf089. doi: 10.1210.
    PubMed     Abstract available
    
    
    
23. SIMONDS WF, Li Y, Jha S
    Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.
    J Clin Endocrinol Metab. 2025;110:931-939.
    PubMed     Abstract available
    
    
    
24. AEKKA A, Arva NC, Ren HZ, Raval M, et al
    Multiplatform Molecular Testing as an Adjunct to Fine Needle Aspiration in the Evaluation of Pediatric Thyroid Nodules.
    J Clin Endocrinol Metab. 2025 Mar 4:dgaf110. doi: 10.1210.
    PubMed     Abstract available
    
    
    February 2025
25. SCAPPATICCIO L, Di Martino N, Ferrazzano P, Maiorino MI, et al
    Prevalence and Management of Complications of Laser Ablation for Benign Thyroid Nodules: A Systematic Review of Literature and Meta-analysis.
    J Clin Endocrinol Metab. 2025 Feb 20:dgaf108. doi: 10.1210.
    PubMed     Abstract available
    
    
    
26. GOLDFARB M, Bustos MA, Moon J, Jackson K, et al
    Pilot Study of Plasma miRNA Signature Panel for Differentiating Single vs Multiglandular Parathyroid Disease.
    J Clin Endocrinol Metab. 2025;110:758-770.
    PubMed     Abstract available
    
    
    
27. LAI ST, Bauer AJ
    Approach to the Pediatric Patient with Thyroid Nodules.
    J Clin Endocrinol Metab. 2025 Feb 13:dgaf090. doi: 10.1210.
    PubMed     Abstract available
    
    
    
28. ZHOU J, Li D, Ren J, Huang C, et al
    Machine Learning: A Multicentre Study on Predicting Lateral Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Feb 8:dgaf070. doi: 10.1210.
    PubMed     Abstract available
    
    
    
29. WANG L, Zhang L, Ma R, Zhang Y, et al
    Semaglutide reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway to suppress papillary thyroid carcinoma growth.
    J Clin Endocrinol Metab. 2025 Feb 5:dgaf053. doi: 10.1210.
    PubMed     Abstract available
    
    
    
30. CIRELLO V, Colombo C, Tosi D, Manzo A, et al
    TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer.
    J Clin Endocrinol Metab. 2025 Feb 1:dgaf056. doi: 10.1210.
    PubMed     Abstract available
    
    
    January 2025
31. TELITI M, Chytiris S, Coperchini F, Cerutti M, et al
    The natural history of cytologically low-risk indeterminate thyroid nodules.
    J Clin Endocrinol Metab. 2025 Jan 29:dgaf052. doi: 10.1210.
    PubMed     Abstract available
    
    
    
32. VAN DER MEEREN MMD, Boers T, de Graaf P, Duvivier KM, et al
    Radiofrequency ablation for thyroid nodules (RATED study) - analysis of a learning curve and predictors of success.
    J Clin Endocrinol Metab. 2025 Jan 29:dgaf058. doi: 10.1210.
    PubMed     Abstract available
    
    
    
33. LI Y, Simonds WF, Chen H
    A Comparative Genomic Analysis of Parathyroid Adenomas and Carcinomas Harboring Heterozygous Germline CDC73 Mutations.
    J Clin Endocrinol Metab. 2025;110:429-440.
    PubMed     Abstract available
    
    
    
34. NAKAI T, Horiuchi K, Okamoto T
    Predicting Tumor Volume in Primary Hyperparathyroidism From Preoperative Clinical Data.
    J Clin Endocrinol Metab. 2025;110:e391-e396.
    PubMed     Abstract available
    
    
    
35. SONG JX, Dong YQ, Han RL, Xie J, et al
    PI3K/AKT/mTOR Activation is Associated with Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas.
    J Clin Endocrinol Metab. 2025 Jan 20:dgaf042. doi: 10.1210.
    PubMed     Abstract available
    
    
    
36. ROBENSHTOK E, Bachar G, Ritter A
    Approach to the Patient with Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
    J Clin Endocrinol Metab. 2025 Jan 2:dgae903. doi: 10.1210.
    PubMed     Abstract available
    
    
    November 2024
37. CHEN Z, Sun W, Fei M, Qian K, et al
    Clinical and Sonographic Differences between RET Fusion-Positive and BRAFV600E in Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Nov 18:dgae803. doi: 10.1210.
    PubMed     Abstract available
    
    
    
38. SCHUMM MA, Nikiforov YE, Nikiforova MN, Wald AI, et al
    Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Nov 14:dgae774. doi: 10.1210.
    PubMed     Abstract available
    
    
    
39. 
    Correction to: "Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics".
    J Clin Endocrinol Metab. 2024 Nov 1:dgae756. doi: 10.1210.
    PubMed    
    
    
    October 2024
40. MENG L, Li H, Fu Y, Yu D, et al
    Somatic DICER1-Mutant Benign Thyroid Nodules in Adults: A Group of Follicular Nodular Disease With Continuous Growth.
    J Clin Endocrinol Metab. 2024 Oct 28:dgae750. doi: 10.1210.
    PubMed     Abstract available
    
    
    
41. PARVATHAREDDY SK, Siraj AK, Qadri Z, Siraj N, et al
    The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 18:dgae740. doi: 10.1210.
    PubMed     Abstract available
    
    
    
42. 
    Correction to: "Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine".
    J Clin Endocrinol Metab. 2024 Oct 16:dgae717. doi: 10.1210.
    PubMed    
    
    
    
43. BEHAIRY N, Leonardi AJ, Gubbi S, Kumari S, et al
    Tumor Volume Doubling Time of Less Than One Year is Associated with a Higher Risk of Death from Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 16:dgae733. doi: 10.1210.
    PubMed     Abstract available
    
    
    
44. KELLY CA, Sipos JA
    Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae722. doi: 10.1210.
    PubMed     Abstract available
    
    
    
45. LEE S, Antunez AG, Sinco B, Saucke MC, et al
    Cancer-related Fear and Worry in Patients with Low-Risk Thyroid Cancer: A Longitudinal Cohort Study.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae688. doi: 10.1210.
    PubMed     Abstract available
    
    
    
46. HSU YC, Kuo CY, Chien MN, Jhuang JY, et al
    Overexpression of NR1D1 portends disease recurrence in thyroid cancer.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae687. doi: 10.1210.
    PubMed     Abstract available
    
    
    
47. MEHANNA H, Nankivell P, Boelaert K, Woolley R, et al
    Diagnostic performance of ultrasound vs. ultrasound-guided FNAc in thyroid nodules: data from the ElaTION trial.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae682. doi: 10.1210.
    PubMed     Abstract available
    
    
    
48. ROTONDI M, Endo M, Teliti M, Crescenzi A, et al
    Beyond malignancy risk stratification: FNAC report anticipates thyroid cancer staging. Insights from recent studies.
    J Clin Endocrinol Metab. 2024 Oct 1:dgae675. doi: 10.1210.
    PubMed     Abstract available
    
    
    September 2024
49. MORETTI S, Mandarano M, Menicali E, Guzzetti M, et al
    Wnt/B-catenin activation and TP53 mutations associate with distinct immune profiles in advanced thyroid cancer.
    J Clin Endocrinol Metab. 2024 Sep 27:dgae667. doi: 10.1210.
    PubMed     Abstract available
    
    
    
50. XU B, Baine MK, Jungbluth A, Alabkaa A, et al
    Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Sep 26:dgae672. doi: 10.1210.
    PubMed     Abstract available
    
    
    
51. ZHANG Y, Zhang X, Lin L, Xing M, et al
    Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae617. doi: 10.1210.
    PubMed     Abstract available
    
    
    
52. MACIEL AAW, Danilovic DLS, Soares IC, Freitas TC, et al
    Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae653. doi: 10.1210.
    PubMed     Abstract available
    
    
    August 2024
53. YUAN J, Chen Z, Zhang J, Chen X, et al
    Preoperative Serum Lipids as Novel Predictors of Survival in 3575 Papillary Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2024 Aug 30:dgae601. doi: 10.1210.
    PubMed     Abstract available
    
    
    
54. MOOIJ CF, Zwaveling-Soonawala N, Hillebrand JJ, van Trotsenburg ASP, et al
    Approach to the Patient: Challenging Cases of Pediatric Thyrotoxicosis.
    J Clin Endocrinol Metab. 2024 Aug 27:dgae592. doi: 10.1210.
    PubMed     Abstract available
    
    
    
55. RAMONE T, Ghirri A, Prete A, Matrone A, et al
    Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae575. doi: 10.1210.
    PubMed     Abstract available
    
    
    
56. XU Y, Gao J, Wang N, Zedenius J, et al
    BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae589. doi: 10.1210.
    PubMed     Abstract available
    
    
    
57. STEGENGA MT, Oudijk L, van Velsen EFS, Peeters RP, et al
    Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.
    J Clin Endocrinol Metab. 2024 Aug 21:dgae581. doi: 10.1210.
    PubMed     Abstract available
    
    
    
58. CASTELLANOS LE, Zafereo ME, Sturgis EM, Wang JR, et al
    Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine.
    J Clin Endocrinol Metab. 2024 Aug 20:dgae576. doi: 10.1210.
    PubMed     Abstract available
    
    
    
59. GRANI G, D'Elia S, Puxeddu E, Morelli S, et al
    Data-Driven Thyroglobulin Cutoffs for Low- and Intermediate-Risk Thyroid Cancer Follow-Up: ITCO Real-World Analysis.
    J Clin Endocrinol Metab. 2024 Aug 16:dgae559. doi: 10.1210.
    PubMed     Abstract available
    
    
    
60. IYER PC, Dadu R, Barque A, Zanelli C, et al
    Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.
    J Clin Endocrinol Metab. 2024;109:2269-2273.
    PubMed     Abstract available
    
    
    
61. LI G, Ye Z, Wei T, Zhu J, et al
    Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC.
    J Clin Endocrinol Metab. 2024;109:2294-2305.
    PubMed     Abstract available
    
    
    
62. ENDO M, Peng J, Nabhan FA, Brock P, et al
    Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules.
    J Clin Endocrinol Metab. 2024;109:2317-2324.
    PubMed     Abstract available
    
    
    
63. KONDA B, Sherman EJ, Massarelli E, Nieva J, et al
    Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 12:dgae512. doi: 10.1210.
    PubMed     Abstract available
    
    
    
64. GHOSH R, Auh S, Gubbi S, Veeraraghavan P, et al
    Association of Free Thyroxine with Progression-Free Survival in Intermediate and High Risk Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Aug 8:dgae537. doi: 10.1210.
    PubMed     Abstract available
    
    
    
65. WANG JR, Zafereo ME, Cabanillas ME, Wu CC, et al
    The association between thyroid differentiation score and survival outcomes in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Aug 1:dgae532. doi: 10.1210.
    PubMed     Abstract available
    
    
    July 2024
66. FENG J, Wu C, Shen F, Cai W, et al
    Second Primary Differentiated Thyroid Carcinoma in Adult Cancer Survivors: A SEER Database Analysis.
    J Clin Endocrinol Metab. 2024 Jul 24:dgae501. doi: 10.1210.
    PubMed     Abstract available
    
    
    
67. WANG H, Li Q, Tian T, Liu B, et al
    Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Jul 9:dgae465. doi: 10.1210.
    PubMed     Abstract available
    
    
    
68. JING R, Wu N, Wu Y, Zhang Q, et al
    Efficacy and safety of multikinase inhibitors for patients with refractory thyroid cancer: Systematic review and network meta-analysis.
    J Clin Endocrinol Metab. 2024 Jul 6:dgae454. doi: 10.1210.
    PubMed     Abstract available
    
    
    
69. 
    Correction to: "TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Jul 1:dgae442. doi: 10.1210.
    PubMed    
    
    
    June 2024
70. SEHGAL K, Serritella A, Liu M, ONeill A, et al
    A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Jun 29:dgae443. doi: 10.1210.
    PubMed     Abstract available
    
    
    
71. PARDI E, Poma AM, Torregrossa L, Pierotti L, et al
    Whole-exome sequencing of atypical parathyroid tumors detects novel and common genes linked to parathyroid tumorigenesis.
    J Clin Endocrinol Metab. 2024 Jun 28:dgae441. doi: 10.1210.
    PubMed     Abstract available
    
    
    
72. WILLIAMS MD, Liu Z, Rossi ED, Agarwal S, et al
    Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.
    J Clin Endocrinol Metab. 2024 Jun 14:dgae354. doi: 10.1210.
    PubMed     Abstract available
    
    
    May 2024
73. CAO H, Shangguan L, Zhu H, Hu C, et al
    Prognostic analysis of 131I efficacy after papillary thyroid carcinoma surgery based on CT radiomics.
    J Clin Endocrinol Metab. 2024 May 27:dgae364. doi: 10.1210.
    PubMed     Abstract available
    
    
    
74. LEVESQUE F, Payne RJ, Beaudoin D, Boucher A, et al
    A Prospective Study of Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience.
    J Clin Endocrinol Metab. 2024 May 23:dgae355. doi: 10.1210.
    PubMed     Abstract available
    
    
    
75. LI G, Chen W, Jiang K, Huang J, et al
    Exosome-mediated Delivery of miR-519e-5p Promotes Malignant Tumor Phenotype and CD8+ T-Cell Exhaustion in Metastatic PTC.
    J Clin Endocrinol Metab. 2024;109:1601-1617.
    PubMed     Abstract available
    
    
    
76. XIAN K, Xu S, Huang H, Xing C, et al
    Synergy of nodal factors in predicting recurrence after treatment of N1b papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 May 15:dgae329. doi: 10.1210.
    PubMed     Abstract available
    
    
    
77. ZHANG W, Lin S, Wang Z, Zhang W, et al
    Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targets in Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 May 13:dgae327. doi: 10.1210.
    PubMed     Abstract available
    
    
    April 2024
78. PETROVIC I, LoPresti J, Fatemi S, Gianoukakis A, et al
    Influence of Thyroglobulin (Tg) Autoantibodies on Tg levels Measured by Different Methodologies: (IMA, LC-MS/MS and RIA).
    J Clin Endocrinol Metab. 2024 Apr 30:dgae286. doi: 10.1210.
    PubMed     Abstract available
    
    
    
79. SANT VR, Radhachandran A, Ivezic V, Lee DT, et al
    From Bench-to-Bedside: How Artificial Intelligence Is Changing Thyroid Nodule Diagnostics.
    J Clin Endocrinol Metab. 2024 Apr 29:dgae277. doi: 10.1210.
    PubMed     Abstract available
    
    
    
80. ABOU AZAR S, Tobias J, Applewhite M, Angelos P, et al
    Medullary Thyroid Cancer: Single Institute Experience over Three Decades and Risk Factors for Recurrence.
    J Clin Endocrinol Metab. 2024 Apr 23:dgae279. doi: 10.1210.
    PubMed     Abstract available
    
    
    
81. CHO YY, Ahn SH, Lee EK, Park YJ, et al
    Malignancy Risk of Follicular Neoplasm (Bethesda IV) With Variable Cutoffs of Tumor Size: A Systemic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2024;109:1383-1392.
    PubMed     Abstract available
    
    
    
82. TODA S, Hiroshima Y, Iwasaki H, Masudo K, et al
    Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
    J Clin Endocrinol Metab. 2024 Apr 17:dgae271. doi: 10.1210.
    PubMed     Abstract available
    
    
    
83. SAKO A, Matsuse M, Saenko V, Tanaka A, et al
    TERT promoter mutations increase tumor aggressiveness by altering TERT mRNA splicing in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Apr 5:dgae220. doi: 10.1210.
    PubMed     Abstract available
    
    
    
84. LIU CQ, Shen CK, Du YX, Li ZM, et al
    Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Apr 4:dgae214. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2024
85. LEE-SAXTON YJ, Egan CE, Bratton BA, Thiesmeyer JW, et al
    Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence.
    J Clin Endocrinol Metab. 2024 Mar 30:dgae203. doi: 10.1210.
    PubMed     Abstract available
    
    
    
86. MAROTTA V, Rocco D, Crocco A, Deiana MG, et al
    Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the real-life.
    J Clin Endocrinol Metab. 2024 Mar 19:dgae181. doi: 10.1210.
    PubMed     Abstract available
    
    
    
87. OHIRA T, Nagao M, Hayashi F, Shimura H, et al
    Effects of Overweight on Risk of Thyroid Nodules in Children and Adolescents: The Fukushima Health Management Survey.
    J Clin Endocrinol Metab. 2024 Mar 13:dgae161. doi: 10.1210.
    PubMed     Abstract available
    
    
    
88. CHEN H, Liu Y, Wang F, Sun J, et al
    MeIS: DNA methylation-based immune response signatures for thyroid nodule diagnostics.
    J Clin Endocrinol Metab. 2024 Mar 7:dgae141. doi: 10.1210.
    PubMed     Abstract available
    
    
    
89. HENSLEY SG, Hu MI, Bassett RL, Ying AK, et al
    Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades.
    J Clin Endocrinol Metab. 2024 Mar 4:dgae133. doi: 10.1210.
    PubMed     Abstract available
    
    
    February 2024
90. JAGANNATH S, Mayilvaganan S
    Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Feb 29:dgae117. doi: 10.1210.
    PubMed    
    
    
    
91. SARKAR R, Bolel P, Kapoor A, Eliseeva E, et al
    An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.
    J Clin Endocrinol Metab. 2024 Feb 29:dgae114. doi: 10.1210.
    PubMed     Abstract available
    
    
    
92. SCHOLFIELD DW, Lopez J, Eagan A, Antal Z, et al
    Response to Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?".
    J Clin Endocrinol Metab. 2024 Feb 28:dgae118. doi: 10.1210.
    PubMed    
    
    
    
93. AHMADI S, Kotwal A, Bikas A, Xiang P, et al
    Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier.
    J Clin Endocrinol Metab. 2024 Feb 28:dgae112. doi: 10.1210.
    PubMed     Abstract available
    
    
    
94. VAN DER TUIN K, Ruano D, Knijnenburg J, van der Luijt RB, et al
    Clinically-relevant Germline Variants in Children with Non-Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Feb 28:dgae107. doi: 10.1210.
    PubMed     Abstract available
    
    
    
95. MAINO F, Botte M, Dalmiglio C, Valerio L, et al
    Prognostic Factors Improving ATA Risk System and Dynamic Risk Stratification in Low- and Intermediate-Risk DTC Patients.
    J Clin Endocrinol Metab. 2024;109:722-729.
    PubMed     Abstract available
    
    
    
96. STEGENGA MT, van Velsen EFS, Oudijk L, Verburg FA, et al
    Clinical and Histopathological Risk Factors for Radioactive Iodine Refractory Follicular and Oncocytic Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Feb 13:dgae084. doi: 10.1210.
    PubMed     Abstract available
    
    
    
97. ALTSHULER B, Bikas A, Pappa T, Marqusee E, et al
    Non-Operative, Active Surveillance of Larger Malignant and Suspicious Thyroid Nodules.
    J Clin Endocrinol Metab. 2024 Feb 13:dgae082. doi: 10.1210.
    PubMed     Abstract available
    
    
    January 2024
98. CONDELLO V, Poma AM, Macerola E, Vignali P, et al
    Prevalence, Molecular Landscape and Clinical Impact of DICER1 and DGCR8 Mutated Follicular-Patterned Thyroid Nodules.
    J Clin Endocrinol Metab. 2024 Jan 22:dgae034. doi: 10.1210.
    PubMed     Abstract available
    
    
    
99. BHARADWAJ MS, Ballal S, Bal C
    Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events.
    J Clin Endocrinol Metab. 2024 Jan 12:dgae024. doi: 10.1210.
    PubMed     Abstract available
    
    
    
100. BUCZYNSKA A, Kosciuszko M, Sidorkiewicz I, Wiatr AA, et al
     Enhancing Angioinvasion Assessment in Papillary Thyroid Cancer via a Biomarker Panel Involving TAC, 8-OHdG and Sortilin.
     J Clin Endocrinol Metab. 2024 Jan 5:dgae007. doi: 10.1210.
     PubMed     Abstract available
     
     
     December 2023
101. KIM BH, Ryu SR, Lee JW, Song CM, et al
     Longitudinal changes in quality of life before and after thyroidectomy in patients with differentiated thyroid cancer.
     J Clin Endocrinol Metab. 2023 Dec 23:dgad748. doi: 10.1210.
     PubMed     Abstract available
     
     
     
102. PAPARODIS R, Livadas S, Karvounis E, Bantouna D, et al
     Elevated Preoperative TPO Ab Titers Decrease Risk for DTC in a Linear Fashion: A Retrospective Analysis of 1635 Cases.
     J Clin Endocrinol Metab. 2023;109:e347-e355.
     PubMed     Abstract available
     
     
     
103. GOLDNER W
     The Role of Age in the Risk Assessment of Differentiated Thyroid Cancers.
     J Clin Endocrinol Metab. 2023 Dec 20:dgad743. doi: 10.1210.
     PubMed    
     
     
     
104. LIN S, Wang Z, Xing M
     Association between a History of Breast Cancer and Decreased Thyroid Cancer-specific Mortality.
     J Clin Endocrinol Metab. 2023 Dec 8:dgad722. doi: 10.1210.
     PubMed     Abstract available
     
     
     
105. MU Z, Zhang X, Sun D, Sun Y, et al
     Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer.
     J Clin Endocrinol Metab. 2023 Dec 7:dgad697. doi: 10.1210.
     PubMed     Abstract available
     
     
     
106. LEUNG AM, Brent GA
     Pregnancy - Does Promotion of Growth Extend to Thyroid Cancer?
     J Clin Endocrinol Metab. 2023 Dec 2:dgad707. doi: 10.1210.
     PubMed    
     
     
     
107. WANG Y, Zou B, Zhang Y, Zhang J, et al
     Comprehensive long-read sequencing analysis discloses the transcriptome features of Papillary Thyroid Microcarcinoma.
     J Clin Endocrinol Metab. 2023 Dec 1:dgad695. doi: 10.1210.
     PubMed     Abstract available
     
     
     November 2023
108. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
     Role of the degree of vascular invasion in predicting prognosis of follicular thyroid carcinoma.
     J Clin Endocrinol Metab. 2023 Nov 25:dgad689. doi: 10.1210.
     PubMed     Abstract available
     
     
     
109. TORA R, Welch J, Sun J, Agarwal SK, et al
     Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
     J Clin Endocrinol Metab. 2023;108:3165-3177.
     PubMed     Abstract available
     
     
     
110. LIU Q, Mao L, Zhang Z, Li G, et al
     Diagnostic Efficacy of FNA-Tg in DTC Cervical LN Metastasis and its Impact Factors: A Large Retrospective Study.
     J Clin Endocrinol Metab. 2023;108:3311-3319.
     PubMed     Abstract available
     
     
     
111. FALCHETTI A
     New Perspective on the Genetic Dissection Underlying the Development of Parathyroid Cancer.
     J Clin Endocrinol Metab. 2023;108:e1751-e1752.
     PubMed    
     
     
     
112. LI P, Liu Y, Wei T, Wang X, et al
     Effect and interactions of BRAF on lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis.
     J Clin Endocrinol Metab. 2023 Nov 15:dgad667. doi: 10.1210.
     PubMed     Abstract available
     
     
     October 2023
113. KWON H, Han KD, Moon SJ, Park SE, et al
     Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.
     J Clin Endocrinol Metab. 2023 Oct 31:dgad575. doi: 10.1210.
     PubMed     Abstract available
     
     
     
114. DAI P, Zhao W, Zheng X, Luo H, et al
     Effect of radioactive iodine therapy on cancer-specific survival of papillary thyroid cancer tall cell variant.
     J Clin Endocrinol Metab. 2023 Oct 7:dgad580. doi: 10.1210.
     PubMed     Abstract available
     
     
     
115. 
     Correction to "The Outcomes of First Reoperation for Locoregionally Recurrent/Persistent Papillary Thyroid Carcinoma in Patients Who Initially Underwent Total Thyroidectomy and Remnant Ablation".
     J Clin Endocrinol Metab. 2023 Oct 3:dgad573. doi: 10.1210.
     PubMed    
     
     
     September 2023
116. PALYGA I, Rumian M, Kosel A, Albrzykowski M, et al
     The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy.
     J Clin Endocrinol Metab. 2023 Sep 28:dgad571. doi: 10.1210.
     PubMed     Abstract available
     
     
     
117. XIAO WC, Li X, Shan R, Mei F, et al
     Pregnancy and progression of differentiated thyroid cancer: A propensity score-matched retrospective cohort study.
     J Clin Endocrinol Metab. 2023 Sep 20:dgad557. doi: 10.1210.
     PubMed     Abstract available
     
     
     
118. POZDEYEV N, Dighe M, Barrio M, Raeburn C, et al
     Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant.
     J Clin Endocrinol Metab. 2023 Sep 8:dgad530. doi: 10.1210.
     PubMed     Abstract available
     
     
     
119. ILGAN S, Aydogan BI, Emer O, Anil C, et al
     Sonographic features of atypical and initially missed parathyroid adenomas: Lessons learned from a single center cohort.
     J Clin Endocrinol Metab. 2023 Sep 5:dgad527. doi: 10.1210.
     PubMed     Abstract available
     
     
     August 2023
120. GILLIS A, Chen H, Wang TS, Dream S, et al
     Racial and Ethnic Disparities in the Diagnosis and Treatment of Thyroid Disease: a Mini- Review.
     J Clin Endocrinol Metab. 2023 Aug 30:dgad519. doi: 10.1210.
     PubMed     Abstract available
     
     
     
121. HA EJ, Lee JH, Lee DH, Moon J, et al
     Artificial Intelligence Model Assisting Thyroid Nodule Diagnosis and Management: A Multicenter Diagnostic Study.
     J Clin Endocrinol Metab. 2023 Aug 25:dgad503. doi: 10.1210.
     PubMed     Abstract available
     
     
     
122. JU G, Sun Y, Wang H, Zhang X, et al
     Fusion oncogenes in patients with locally advanced or distant metastatic differentiated thyroid cancer.
     J Clin Endocrinol Metab. 2023 Aug 25:dgad500. doi: 10.1210.
     PubMed     Abstract available
     
     
     
123. LI H, Han R, Meng L, Sun Y, et al
     Nodal Metastases Associated with Fusion Oncogenes Are Age Dependent in Young Adult Patients with Thyroid Cancer.
     J Clin Endocrinol Metab. 2023 Aug 3:dgad458. doi: 10.1210.
     PubMed     Abstract available
     
     
     July 2023
124. MERCADO M
     The Role of Androgen Receptors in Thyroid Cancer Biology: Beyond Sexual Dimorphism.
     J Clin Endocrinol Metab. 2023 Jul 15:dgad424. doi: 10.1210.
     PubMed    
     
     
     
125. NOEL JE, Sinclair CF
     Radiofrequency Ablation for Benign Thyroid Nodules.
     J Clin Endocrinol Metab. 2023 Jul 4:dgad357. doi: 10.1210.
     PubMed     Abstract available
     
     
     June 2023
126. YAN L, Zhen Y, Li Y, Li X, et al
     Five-year Outcome Between Radiofrequency Ablation vs. Surgery for Unilateral Multifocal Papillary Thyroid Microcarcinoma.
     J Clin Endocrinol Metab. 2023 Jun 15:dgad360. doi: 10.1210.
     PubMed     Abstract available
     
     
     
127. YEH MW
     The molecular landscape of thyroid nodules: Diagnostic and prognostic revelations from a large multicenter cohort.
     J Clin Endocrinol Metab. 2023 Jun 15:dgad362. doi: 10.1210.
     PubMed    
     
     
     
128. SATAPATHY S, Majeed AK, Ballal S, Bal C, et al
     Differentiated thyroid cancers in young adults versus children: Clinical characteristics and ten-year follow-up outcomes.
     J Clin Endocrinol Metab. 2023 Jun 7:dgad343. doi: 10.1210.
     PubMed     Abstract available
     
     
     
129. ZHOU Y, Wang Y, Zhang Z, Yin X, et al
     Male sex is not a risk factor for prognosis in postoperative thyroid cancer patients: a propensity score matching study.
     J Clin Endocrinol Metab. 2023 Jun 2:dgad314. doi: 10.1210.
     PubMed     Abstract available
     
     
     
130. BOJARSKY M, Baran JA, Halada S, Isaza A, et al
     Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated with Radioactive Iodine Therapy.
     J Clin Endocrinol Metab. 2023 Jun 2:dgad322. doi: 10.1210.
     PubMed     Abstract available
     
     
     May 2023
131. LIN Y, Wu ZR, Shi YP, Ding M, et al
     Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation.
     J Clin Endocrinol Metab. 2023 May 23:dgad269. doi: 10.1210.
     PubMed     Abstract available
     
     
     
132. CHOU CK, Chi SY, Hung YY, Yang YC, et al
     Clinical impact of androgen receptor-suppressing miR-146b expression in papillary thyroid cancer aggressiveness.
     J Clin Endocrinol Metab. 2023 May 23:dgad279. doi: 10.1210.
     PubMed     Abstract available
     
     
     
133. ALZAHRANI AS
     Clinical use of molecular data in thyroid nodules and cancer.
     J Clin Endocrinol Metab. 2023 May 18:dgad282. doi: 10.1210.
     PubMed     Abstract available
     
     
     
134. SUN Y, Sun Q, Tian J, He X, et al
     Impact of waiting time for radioactive iodine therapy on outcome in N1 stage papillary thyroid cancer.
     J Clin Endocrinol Metab. 2023 May 11:dgad264. doi: 10.1210.
     PubMed     Abstract available
     
     
     April 2023
135. ULLMANN TM, Sosa JA
     Delay in Surgery for Papillary Thyroid Cancer: A Proxy for Lower-Quality Care?
     J Clin Endocrinol Metab. 2023 Apr 21:dgad232. doi: 10.1210.
     PubMed    
     
     
     
136. CHIOSEA S, Hodak SP, Yip L, Abraham D, et al
     Molecular Profiling of 50,734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
     J Clin Endocrinol Metab. 2023 Apr 18:dgad220. doi: 10.1210.
     PubMed     Abstract available
     
     
     March 2023
137. ALZAHRANI AS
     The risk of expanding risk stratification in thyroid cancer.
     J Clin Endocrinol Metab. 2023 Mar 29:dgad182. doi: 10.1210.
     PubMed    
     
     
     
138. CHAVES N, Broekhuis JM, Fligor SC, Collins RA, et al
     Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: a SEER-Medicare Analysis.
     J Clin Endocrinol Metab. 2023 Mar 29:dgad163. doi: 10.1210.
     PubMed     Abstract available
     
     
     
139. VAN VELSEN EFS, Verburg FA
     Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer - To Treat or Not To Treat.
     J Clin Endocrinol Metab. 2023 Mar 25:dgad171. doi: 10.1210.
     PubMed    
     
     
     
140. KESBY N, Mechera R, Fuchs T, Papachristos A, et al
     Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.
     J Clin Endocrinol Metab. 2023 Mar 25:dgad173. doi: 10.1210.
     PubMed     Abstract available
     
     
     
141. NASR CE
     Can one predict long-term growth of cytologically-benign thyroid nodules?
     J Clin Endocrinol Metab. 2023 Mar 22:dgad160. doi: 10.1210.
     PubMed    
     
     
     
142. JHA S, Welch J, Tora R, Lack J, et al
     Germline and somatic inactivating FLCN variants in parathyroid cancer and atypical parathyroid tumors.
     J Clin Endocrinol Metab. 2023 Mar 20:dgad136. doi: 10.1210.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.